Clinical Trial Update: Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia [Phase 2]

View source ↗

Summary

The clinical trial update indicates that the Phase 2 study of nivolumab-based immunotherapy for high-grade cervical dysplasia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Dysplasia

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Cervix Uteri--Diseases | Phase 2 | Status: WITHDRAWN